SCHEMBL504480

SCHEMBL504480

CC(=O)NCN[C@H](C(=O)O)C(C)(C)S

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.36
MAPT P10636 2/20 0.36
PTGS1 P23219 1/20 0.36
KDM4E B2RXH2 3/20 0.34
MAPK1 P28482 1/20 0.34
HIF1A Q16665 1/20 0.34
THRB P10828 1/20 0.33
ALOX15 P16050 1/20 0.33
NFKB1 P19838 1/20 0.33
PTGS2 P35354 1/20 0.33
THPO P40225 1/20 0.33
RECQL P46063 1/20 0.33
BLM P54132 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
MTNR1A P48039 2/20 0.33
MTNR1B P49286 2/20 0.33
ADRA1A P35348 1/20 0.32
TSHR P16473 1/20 0.32
NPSR1 Q6W5P4 1/20 0.31
FOLH1 Q04609 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14935873 1.00 ALDH1A1 (0.36) ALDH1A1MAPTPTGS1KDM4EMAPK1
SCHEMBL21403573 0.78 ALDH1A1 (0.43) ALDH1A1MAPTPTGS1KDM4ETHRB
SCHEMBL8769242 0.76 ALDH1A1 (0.41) ALDH1A1MAPTPTGS1
N-Acetyl Penicillamine SCHEMBL4468919 0.74 MAPT (0.43) ALDH1A1MAPTPTGS1KDM4ETHRB
N-Acetyl Penicillamine SCHEMBL34351 0.74 MAPT (0.43) ALDH1A1MAPTPTGS1KDM4ETHRB
N-Acetyl Penicillamine SCHEMBL521764 0.74 MAPT (0.43) ALDH1A1MAPTPTGS1KDM4ETHRB
SCHEMBL30317213 0.71 ALDH1A1 (0.44) ALDH1A1MAPTPTGS1
SCHEMBL31668698 0.71 ALDH1A1 (0.44) ALDH1A1MAPTPTGS1
SCHEMBL3109035 0.70 ALDH1A1 (0.36) ALDH1A1MAPTPTGS1FOLH1
SCHEMBL31196416 0.70 ALOX15 (0.38) ALDH1A1MAPTPTGS1MAPK1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120027720-A1 PEPTIDE CONJUGATES ALBA THERAPEUTICS CORPORATION 2012-02-02 US disclosed
EP-1917020-A1 MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS Seattle Genetics, Inc. (US) 2008-05-07 EP disclosed
WO-2007008603-A1 MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS SEATTLE GENETICS, INC. (US) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120027720-A1 PEPTIDE CONJUGATES VIP, IAPP, NGLY1 ALDH1A1 3745/4885MAPT 1581/4885PTGS1 4292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.